Exelixis, Inc. (EXEL)
USD 35.2
(2.15%)
USD 35.2
(2.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.94 Billion USD | -4.2% |
| 2022 | 3.07 Billion USD | 17.4% |
| 2021 | 2.61 Billion USD | 22.41% |
| 2020 | 2.13 Billion USD | 13.35% |
| 2019 | 1.88 Billion USD | 32.58% |
| 2018 | 1.42 Billion USD | 117.05% |
| 2017 | 655.29 Million USD | 9.67% |
| 2016 | 597.54 Million USD | 79.8% |
| 2015 | 332.34 Million USD | 1.34% |
| 2014 | 327.96 Million USD | -34.84% |
| 2013 | 503.28 Million USD | -30.21% |
| 2012 | 721.09 Million USD | 83.36% |
| 2011 | 393.26 Million USD | 9.0% |
| 2010 | 360.79 Million USD | 5.06% |
| 2009 | 343.41 Million USD | -14.49% |
| 2008 | 401.62 Million USD | -2.55% |
| 2007 | 412.12 Million USD | 4.22% |
| 2006 | 395.41 Million USD | 18.85% |
| 2005 | 332.71 Million USD | 14.2% |
| 2004 | 291.34 Million USD | -18.57% |
| 2003 | 357.79 Million USD | 5.51% |
| 2002 | 339.11 Million USD | -2.16% |
| 2001 | 346.61 Million USD | 69.15% |
| 2000 | 204.91 Million USD | 984.2% |
| 1999 | 18.9 Million USD | 110.44% |
| 1998 | 8.98 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.96 Billion USD | 6.75% |
| 2024 Q1 | 2.8 Billion USD | -4.71% |
| 2024 Q2 | 2.77 Billion USD | -1.09% |
| 2023 Q3 | 2.97 Billion USD | -5.27% |
| 2023 Q4 | 2.94 Billion USD | -1.16% |
| 2023 Q2 | 3.14 Billion USD | -0.03% |
| 2023 Q1 | 3.14 Billion USD | 2.34% |
| 2023 FY | 2.94 Billion USD | -4.2% |
| 2022 Q4 | 3.07 Billion USD | 3.72% |
| 2022 FY | 3.07 Billion USD | 17.4% |
| 2022 Q1 | 2.65 Billion USD | 1.45% |
| 2022 Q2 | 2.88 Billion USD | 8.56% |
| 2022 Q3 | 2.96 Billion USD | 2.78% |
| 2021 Q1 | 2.19 Billion USD | 2.49% |
| 2021 Q2 | 2.36 Billion USD | 8.07% |
| 2021 FY | 2.61 Billion USD | 22.41% |
| 2021 Q4 | 2.61 Billion USD | 6.88% |
| 2021 Q3 | 2.44 Billion USD | 3.4% |
| 2020 Q3 | 2.11 Billion USD | 3.15% |
| 2020 Q4 | 2.13 Billion USD | 1.25% |
| 2020 FY | 2.13 Billion USD | 13.35% |
| 2020 Q1 | 1.95 Billion USD | 3.71% |
| 2020 Q2 | 2.04 Billion USD | 4.65% |
| 2019 Q2 | 1.64 Billion USD | 6.57% |
| 2019 FY | 1.88 Billion USD | 32.58% |
| 2019 Q1 | 1.54 Billion USD | 8.4% |
| 2019 Q4 | 1.88 Billion USD | 5.65% |
| 2019 Q3 | 1.78 Billion USD | 8.63% |
| 2018 Q3 | 1.02 Billion USD | 12.42% |
| 2018 FY | 1.42 Billion USD | 117.05% |
| 2018 Q4 | 1.42 Billion USD | 38.85% |
| 2018 Q2 | 911.15 Million USD | 17.58% |
| 2018 Q1 | 774.91 Million USD | 18.25% |
| 2017 Q3 | 609.77 Million USD | 18.05% |
| 2017 Q1 | 586.98 Million USD | -1.77% |
| 2017 FY | 655.29 Million USD | 9.67% |
| 2017 Q4 | 655.29 Million USD | 7.47% |
| 2017 Q2 | 516.53 Million USD | -12.0% |
| 2016 Q3 | 548.49 Million USD | 14.95% |
| 2016 Q4 | 597.54 Million USD | 8.94% |
| 2016 Q1 | 492.53 Million USD | 48.2% |
| 2016 Q2 | 477.13 Million USD | -3.13% |
| 2016 FY | 597.54 Million USD | 79.8% |
| 2015 Q3 | 363.24 Million USD | 46.01% |
| 2015 Q4 | 332.34 Million USD | -8.51% |
| 2015 Q1 | 282.93 Million USD | -13.73% |
| 2015 FY | 332.34 Million USD | 1.34% |
| 2015 Q2 | 248.77 Million USD | -12.07% |
| 2014 Q1 | 497.56 Million USD | -1.14% |
| 2014 FY | 327.96 Million USD | -34.84% |
| 2014 Q3 | 383.65 Million USD | -12.93% |
| 2014 Q4 | 327.96 Million USD | -14.52% |
| 2014 Q2 | 440.63 Million USD | -11.44% |
| 2013 Q3 | 555.95 Million USD | -9.17% |
| 2013 Q2 | 612.08 Million USD | -7.19% |
| 2013 Q1 | 659.52 Million USD | -8.54% |
| 2013 FY | 503.28 Million USD | -30.21% |
| 2013 Q4 | 503.28 Million USD | -9.47% |
| 2012 FY | 721.09 Million USD | 83.36% |
| 2012 Q1 | 412.6 Million USD | 4.92% |
| 2012 Q2 | 374.48 Million USD | -9.24% |
| 2012 Q3 | 762.61 Million USD | 103.64% |
| 2012 Q4 | 721.09 Million USD | -5.44% |
| 2011 FY | 393.26 Million USD | 9.0% |
| 2011 Q4 | 393.26 Million USD | -4.46% |
| 2011 Q3 | 411.63 Million USD | -9.37% |
| 2011 Q2 | 454.18 Million USD | -8.38% |
| 2011 Q1 | 495.73 Million USD | 37.4% |
| 2010 FY | 360.79 Million USD | 5.06% |
| 2010 Q3 | 372.9 Million USD | -11.15% |
| 2010 Q1 | 284.22 Million USD | -17.24% |
| 2010 Q4 | 360.79 Million USD | -3.25% |
| 2010 Q2 | 419.72 Million USD | 47.68% |
| 2009 Q4 | 343.41 Million USD | -18.45% |
| 2009 Q3 | 421.1 Million USD | 26.39% |
| 2009 FY | 343.41 Million USD | -14.49% |
| 2009 Q2 | 333.17 Million USD | -6.18% |
| 2009 Q1 | 355.1 Million USD | -11.58% |
| 2008 Q3 | 254.76 Million USD | -19.54% |
| 2008 Q4 | 401.62 Million USD | 57.65% |
| 2008 Q1 | 370.57 Million USD | -10.08% |
| 2008 FY | 401.62 Million USD | -2.55% |
| 2008 Q2 | 316.62 Million USD | -14.56% |
| 2007 Q4 | 412.12 Million USD | -1.94% |
| 2007 Q1 | 420.63 Million USD | 6.38% |
| 2007 Q3 | 420.29 Million USD | 13.05% |
| 2007 FY | 412.12 Million USD | 4.22% |
| 2007 Q2 | 371.78 Million USD | -11.61% |
| 2006 Q4 | 395.41 Million USD | 46.1% |
| 2006 FY | 395.41 Million USD | 18.85% |
| 2006 Q3 | 270.65 Million USD | -11.69% |
| 2006 Q2 | 306.47 Million USD | -9.21% |
| 2006 Q1 | 337.58 Million USD | 1.46% |
| 2005 Q1 | 269.75 Million USD | -7.41% |
| 2005 Q2 | 325.14 Million USD | 20.53% |
| 2005 Q4 | 332.71 Million USD | -1.77% |
| 2005 Q3 | 338.7 Million USD | 4.17% |
| 2005 FY | 332.71 Million USD | 14.2% |
| 2004 Q3 | 267.86 Million USD | -6.73% |
| 2004 Q4 | 291.34 Million USD | 8.76% |
| 2004 Q1 | 321.65 Million USD | -10.1% |
| 2004 FY | 291.34 Million USD | -18.57% |
| 2004 Q2 | 287.19 Million USD | -10.71% |
| 2003 Q4 | 357.79 Million USD | 6.23% |
| 2003 FY | 357.79 Million USD | 5.51% |
| 2003 Q1 | 320.82 Million USD | -5.39% |
| 2003 Q2 | 359.23 Million USD | 11.97% |
| 2003 Q3 | 336.82 Million USD | -6.24% |
| 2002 Q4 | 339.11 Million USD | 21.41% |
| 2002 FY | 339.11 Million USD | -2.16% |
| 2002 Q1 | 320.93 Million USD | -7.41% |
| 2002 Q2 | 298.36 Million USD | -7.03% |
| 2002 Q3 | 279.3 Million USD | -6.39% |
| 2001 Q1 | 196.05 Million USD | -4.32% |
| 2001 FY | 346.61 Million USD | 69.15% |
| 2001 Q3 | 246.71 Million USD | 3.44% |
| 2001 Q4 | 346.61 Million USD | 40.49% |
| 2001 Q2 | 238.51 Million USD | 21.66% |
| 2000 Q3 | 144.38 Million USD | -1.7% |
| 2000 Q2 | 146.88 Million USD | 399.68% |
| 2000 Q1 | 29.39 Million USD | 0.0% |
| 2000 Q4 | 204.91 Million USD | 41.92% |
| 2000 FY | 204.91 Million USD | 984.2% |
| 1999 FY | 18.9 Million USD | 110.44% |
| 1998 FY | 8.98 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 440.96 Million USD | -567.25% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -20182.819% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -35508.822% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -5090.074% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -610.986% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -681.604% |
| Agenus Inc. | 313.91 Million USD | -837.316% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1656.358% |
| GlycoMimetics, Inc. | 45.31 Million USD | -6392.908% |
| Novavax, Inc. | 1.85 Billion USD | -58.588% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -695.178% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -9170.186% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -549.475% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -527.112% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -1117.344% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 23.174% |
| AlloVir, Inc. | 190.79 Million USD | -1442.148% |
| Aptorum Group Limited | 20.64 Million USD | -14155.543% |
| Ardelyx, Inc. | 297.57 Million USD | -888.765% |
| Bicycle Therapeutics plc | 595.34 Million USD | -394.228% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -3892.235% |
| Chimerix, Inc. | 212.77 Million USD | -1282.856% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -10307.174% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -31.97% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -8549.412% |
| Precision BioSciences, Inc. | 159.78 Million USD | -1741.494% |
| Dyadic International, Inc. | 8.21 Million USD | -35698.425% |
| Elevation Oncology, Inc. | 89.09 Million USD | -3202.642% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1656.358% |
| GT Biopharma, Inc. | 14.1 Million USD | -20754.469% |
| Alkermes plc | 2.13 Billion USD | -37.736% |
| Immix Biopharma, Inc. | 19.92 Million USD | -14667.043% |
| Innoviva, Inc. | 1.24 Billion USD | -136.618% |
| IO Biotech, Inc. | 150.71 Million USD | -1852.227% |
| Jaguar Health, Inc. | 50.76 Million USD | -5696.263% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -253.197% |
| ContextLogic Inc. | 423 Million USD | -595.593% |
| AbCellera Biologics Inc. | 1.48 Billion USD | -97.727% |
| Lantern Pharma Inc. | 43.64 Million USD | -6641.163% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -47342.067% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -284.344% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -359.351% |
| MEI Pharma, Inc. | 41.37 Million USD | -7011.437% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -1271.69% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -15448.55% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -1621.603% |
| NextCure, Inc. | 129.41 Million USD | -2173.53% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -1723.734% |
| ChromaDex Corporation | 54.96 Million USD | -5253.244% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -353.147% |
| Incyte Corporation | 6.78 Billion USD | 56.616% |
| Opthea Limited | 188.79 Million USD | -1458.524% |
| MiMedx Group, Inc. | 239.04 Million USD | -1130.87% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -9009.182% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -2121.938% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -259789.026% |
| Vaxcyte, Inc. | 1.4 Billion USD | -108.987% |
| PDS Biotechnology Corporation | 59.39 Million USD | -4854.29% |
| Pharming Group N.V. | 462.85 Million USD | -535.699% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -7506.921% |
| Onconetix, Inc. | 88.82 Million USD | -3212.665% |
| Acelyrin, Inc. | 742.69 Million USD | -296.176% |
| PureTech Health plc | 693.97 Million USD | -323.987% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -1593.677% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -368.114% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -56815.419% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -15448.55% |
| ESSA Pharma Inc. | 149.12 Million USD | -1873.119% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -2410.008% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -5354.061% |
| Seer, Inc. | 436.26 Million USD | -574.436% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1679.795% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -45852.788% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -6397.134% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -44572.386% |
| Summit Therapeutics Inc. | 202.94 Million USD | -1349.801% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -3856.163% |
| Senti Biosciences, Inc. | 119.48 Million USD | -2362.553% |
| ImmuCell Corporation | 43.8 Million USD | -6616.468% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -1649.591% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -673.476% |
| Precigen, Inc. | 151.04 Million USD | -1848.026% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -5703.809% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -7910.991% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -1188.575% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -763.373% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -61535.945% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -522.273% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -3505.962% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -2279.527% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -2912.087% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -8979.667% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -970.146% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -481.244% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -29017.833% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -855.643% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -523.504% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -2990.322% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -465766.514% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -419.538% |
| Aptose Biosciences Inc. | 12.92 Million USD | -22669.178% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -13205.233% |
| Soligenix, Inc. | 9.79 Million USD | -29932.246% |
| Century Therapeutics, Inc. | 360.69 Million USD | -715.756% |
| Kura Oncology, Inc. | 448.93 Million USD | -555.408% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -981.157% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -16912.761% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -2552.891% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -1334.24% |
| Autolus Therapeutics plc | 375.38 Million USD | -683.832% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -1069.291% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -728.404% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -5888.677% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -345.047% |
| GRI Bio, Inc. | 2.95 Million USD | -99438.464% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -27644.406% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -1625.571% |
| IGM Biosciences, Inc. | 423.41 Million USD | -594.917% |
| INmune Bio, Inc. | 57 Million USD | -5061.939% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1222.372% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3405.257% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -11166.122% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -42646.966% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -3811.356% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -1898.097% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1677.816% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -367.335% |
| Verastem, Inc. | 149.71 Million USD | -1865.266% |
| Abeona Therapeutics Inc. | 64 Million USD | -4497.289% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -474.506% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -1804.968% |
| Histogen Inc. | 19.07 Million USD | -15326.818% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -12890.439% |
| Surrozen, Inc. | 46.08 Million USD | -6285.323% |
| Organovo Holdings, Inc. | 6.34 Million USD | -46243.629% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -68190.009% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -1942.924% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -24831.003% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -3809.174% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -34437.747% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -710.636% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -16161.15% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -585.222% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -23230.339% |
| Apollomics, Inc. | 55.38 Million USD | -5212.36% |
| Amarin Corporation plc | 831.68 Million USD | -253.783% |
| Mesoblast Limited | 669.15 Million USD | -339.714% |
| Turnstone Biologics Corp. | 112.81 Million USD | -2508.126% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -411.04% |
| Synaptogenix, Inc. | 31.11 Million USD | -9356.799% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -24049.352% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -436.866% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -50006.032% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -39958.452% |
| Better Therapeutics, Inc. | 22.94 Million USD | -12724.639% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -707.145% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -273.05% |
| NLS Pharmaceutics AG | 1.84 Million USD | -159235.626% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -36777.954% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -19922.845% |
| Gritstone bio, Inc. | 177.76 Million USD | -1555.158% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -2984.878% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -16372.47% |
| Avid Bioservices, Inc. | 336.55 Million USD | -774.252% |
| Insmed Incorporated | 1.32 Billion USD | -121.257% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -30459.323% |
| MediWound Ltd. | 66.45 Million USD | -4327.327% |
| OmniAb, Inc. | 401.98 Million USD | -631.957% |
| Alector, Inc. | 621.82 Million USD | -373.179% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -720.512% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -54610.989% |
| Zai Lab Limited | 1.03 Billion USD | -183.93% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -514.972% |
| Aura Biosciences, Inc. | 255.07 Million USD | -1053.526% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -292.299% |
| Immunic, Inc. | 54.29 Million USD | -5318.805% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -1005.219% |
| Veracyte, Inc. | 1.13 Billion USD | -158.596% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -24787.18% |
| FibroGen, Inc. | 423.52 Million USD | -594.724% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -83656.248% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -62019.535% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -54092.263% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 74.175% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -33316.888% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -468.622% |
| TG Therapeutics, Inc. | 329.58 Million USD | -792.741% |
| Galecto, Inc. | 38.22 Million USD | -7597.065% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -10160.695% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 32.471% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -1149.918% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -11744.284% |
| XBiotech Inc. | 227.24 Million USD | -1194.806% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -2984.878% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -1963.364% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -929.098% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -2201.071% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -670.253% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -97.339% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -706.474% |
| Vaxxinity, Inc. | 44.35 Million USD | -6533.953% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -469.165% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -15711.192% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -864.549% |
| NexImmune, Inc. | 8.59 Million USD | -34137.543% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -27359.681% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -17079.248% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 91.105% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -13183.101% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -749994.197% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -1597.556% |
| Ainos, Inc. | 31.84 Million USD | -9140.547% |
| Pluri Inc. | 39.52 Million USD | -7343.917% |
| Prothena Corporation plc | 696.38 Million USD | -322.521% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -941.115% |
| Celularity Inc. | 143.88 Million USD | -1944.88% |
| Rallybio Corporation | 115.62 Million USD | -2444.851% |
| Cue Biopharma, Inc. | 61.53 Million USD | -4681.988% |
| MeiraGTx Holdings plc | 458.16 Million USD | -542.2% |
| Omeros Corporation | 378.26 Million USD | -677.848% |
| Humacyte, Inc. | 128.22 Million USD | -2194.719% |
| Immunocore Holdings plc | 597 Million USD | -392.856% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -9312.832% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -4193.531% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -180.425% |
| CalciMedica, Inc. | 12.18 Million USD | -24047.37% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -1060.007% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -845.989% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -420.496% |
| Pulmatrix, Inc. | 33.95 Million USD | -8564.695% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -10739.008% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -1988.882% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -126.165% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -2160.065% |
| Cytokinetics, Incorporated | 824.31 Million USD | -256.945% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -13829.636% |
| Nutriband Inc. | 7.51 Million USD | -39041.901% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -3626.672% |
| Vor Biopharma Inc. | 209.82 Million USD | -1302.271% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 59.261% |
| Evogene Ltd. | 51.1 Million USD | -5657.925% |
| ProKidney Corp. | 420.55 Million USD | -599.642% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -5266.033% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -30806.209% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -438.518% |
| CorMedix Inc. | 82.05 Million USD | -3485.619% |
| BioLineRx Ltd. | 63.92 Million USD | -4502.827% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -630.899% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -10333.89% |
| Atai Life Sciences N.V. | 293.47 Million USD | -902.582% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -1703.695% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -2209.216% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -423.526% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -2942.171% |
| MediciNova, Inc. | 66.26 Million USD | -4339.955% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -3245.564% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -65837.166% |
| GeoVax Labs, Inc. | 9.28 Million USD | -31595.439% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -400.2% |
| Biomea Fusion, Inc. | 199.92 Million USD | -1371.716% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -54.602% |
| Mereo BioPharma Group plc | 66.49 Million USD | -4324.664% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -506.551% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -380.087% |
| Absci Corporation | 234.48 Million USD | -1154.843% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -40123.609% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -765.677% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -1682.361% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -459.041% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -959.572% |
| Allakos Inc. | 243.61 Million USD | -1107.815% |
| Imunon, Inc. | 21.91 Million USD | -13324.344% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -1041.803% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -373.415% |
| BioAtla, Inc. | 119.65 Million USD | -2358.972% |
| NLS Pharmaceutics AG | 1.84 Million USD | -159235.626% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -91277.547% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -357.714% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -2967.032% |
| XOMA Corporation | 234.3 Million USD | -1155.802% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -1229.969% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2238.099% |
| aTyr Pharma, Inc. | 122.06 Million USD | -2310.444% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -1811.826% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -407.066% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -499.962% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -2563.514% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -19311.813% |
| Akari Therapeutics, Plc | 4.35 Million USD | -67462.732% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -17170.056% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -69.758% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -95307.599% |
| UroGen Pharma Ltd. | 178.31 Million USD | -1550.126% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -525.055% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -529372.301% |
| Orgenesis Inc. | 14.55 Million USD | -20119.606% |
| Entera Bio Ltd. | 11.76 Million USD | -24909.409% |
| GH Research PLC | 226.3 Million USD | -1200.202% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -5279.671% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -2638.707% |
| Xencor, Inc. | 952.69 Million USD | -208.847% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -37701.176% |
| Replimune Group, Inc. | 487.72 Million USD | -503.286% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -36355.514% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -353.759% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -95307.599% |
| Portage Biotech Inc. | 7.77 Million USD | -37724.36% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -65837.166% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -962.434% |
| OncoCyte Corporation | 74.89 Million USD | -3828.8% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -144612.155% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -50747.391% |
| Purple Biotech Ltd. | 44.3 Million USD | -6541.59% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -8522.039% |
| scPharmaceuticals Inc. | 94.47 Million USD | -3014.297% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -16205.702% |
| HilleVax, Inc. | 344.43 Million USD | -754.259% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -92543.482% |
| Tharimmune, Inc. | 10.94 Million USD | -26779.695% |
| Genprex, Inc. | 10.67 Million USD | -27474.449% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -492.984% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -2956.931% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -121184.295% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -70537.347% |
| OKYO Pharma Limited | 1.54 Million USD | -190805.452% |
| Savara Inc. | 177.56 Million USD | -1557.068% |
| Curis, Inc. | 77.28 Million USD | -3707.299% |
| Daré Bioscience, Inc. | 21.28 Million USD | -13725.427% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -4501.113% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -36288.288% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -15089.495% |
| BeiGene, Ltd. | 5.8 Billion USD | 49.316% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -24079.119% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -40.878% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -722.0% |
| Erasca, Inc. | 395.29 Million USD | -644.341% |
| bluebird bio, Inc. | 619.16 Million USD | -375.217% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -67957.041% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 56.993% |
| DBV Technologies S.A. | 182.98 Million USD | -1507.968% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -67957.041% |
| Moderna, Inc. | 18.42 Billion USD | 84.031% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -16051.71% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -25295.797% |
| Molecular Templates, Inc. | 35.38 Million USD | -8215.736% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -2028.056% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -272.963% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -868.661% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -2730.659% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -531.913% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -838.74% |
| MacroGenics, Inc. | 306.82 Million USD | -858.985% |
| RenovoRx, Inc. | 1.46 Million USD | -200606.48% |
| Adicet Bio, Inc. | 207.29 Million USD | -1319.406% |
| Prime Medicine, Inc. | 193.85 Million USD | -1417.845% |
| Aditxt, Inc. | 44.57 Million USD | -6500.42% |
| Adagene Inc. | 115.72 Million USD | -2442.458% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -65958.198% |
| Quantum-Si incorporated | 298.25 Million USD | -886.54% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -97.812% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -38067.208% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -737.608% |
| SciSparc Ltd. | 11.18 Million USD | -26213.334% |
| Vericel Corporation | 353.65 Million USD | -731.98% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -23992.78% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -5071.046% |
| Generation Bio Co. | 374.75 Million USD | -685.135% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -1055.379% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -1755.592% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -761.939% |
| Invivyd, Inc. | 229.18 Million USD | -1183.857% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -248.629% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -24078.521% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -1513.223% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -14306.37% |
| 2seventy bio, Inc. | 565.42 Million USD | -420.379% |
| ADMA Biologics, Inc. | 329.18 Million USD | -793.839% |
| Clene Inc. | 52.34 Million USD | -5521.515% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -4909.604% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -2165.199% |
| GeoVax Labs, Inc. | 9.28 Million USD | -31595.439% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -350.109% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -2739.807% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -2156.651% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -2916.192% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -4044.34% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -1113.078% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -50.113% |
| Evaxion Biotech A/S | 12.88 Million USD | -22729.11% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -1067.324% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -290.913% |
| Trevena, Inc. | 40.6 Million USD | -7146.292% |
| Surrozen, Inc. | 46.08 Million USD | -6285.323% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -1202.752% |
| Cingulate Inc. | 3.49 Million USD | -84173.548% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -17594.131% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4379.155% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -25081.437% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -995.781% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -292.861% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -2237.207% |
| Clearmind Medicine Inc. | 4.32 Million USD | -67940.988% |
| Kronos Bio, Inc. | 213.27 Million USD | -1279.581% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -1741.459% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -34270.88% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -698.49% |
| Statera Biopharma, Inc. | 21.16 Million USD | -13798.917% |
| ImmunityBio, Inc. | 504.45 Million USD | -483.278% |
| Korro Bio, Inc. | 221.66 Million USD | -1227.401% |
| Kineta, Inc. | 10.28 Million USD | -28519.366% |
| BioVie Inc. | 25.2 Million USD | -11572.155% |
| Codexis, Inc. | 136.56 Million USD | -2054.61% |
| Celularity Inc. | 143.88 Million USD | -1944.88% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -363.106% |
| Celcuity Inc. | 191.21 Million USD | -1438.734% |
| Virax Biolabs Group Limited | 5.48 Million USD | -53553.786% |
| Cibus, Inc. | 544.41 Million USD | -440.466% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -2237.17% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -14222.221% |
| IN8bio, Inc. | 33.7 Million USD | -8628.699% |
| Kodiak Sciences Inc. | 479.37 Million USD | -513.794% |
| Annexon, Inc. | 297.67 Million USD | -888.449% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -1600.686% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -2040.379% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -13915.896% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 1.596% |
| Eyenovia, Inc. | 28.77 Million USD | -10123.839% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -1176.356% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -40630.302% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -4729.395% |
| Arcellx, Inc. | 825.13 Million USD | -256.592% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -3504.195% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -536.495% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -9468.641% |
| Moolec Science SA | 24.05 Million USD | -12133.677% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -848.765% |
| Geron Corporation | 394.07 Million USD | -646.647% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -2792.889% |
| Royalty Pharma plc | 16.38 Billion USD | 82.039% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -394.54% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -41964.829% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -24363.954% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -1201.582% |
| Humacyte, Inc. | 128.22 Million USD | -2194.719% |
| Structure Therapeutics Inc. | 482.01 Million USD | -510.426% |
| 89bio, Inc. | 596.26 Million USD | -393.461% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -1066.898% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -158946.324% |
| Genelux Corporation | 27.89 Million USD | -10448.729% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -3191.117% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -1182.47% |
| Notable Labs, Ltd. | 19.54 Million USD | -14957.351% |
| Liquidia Corporation | 120.43 Million USD | -2343.189% |
| Mustang Bio, Inc. | 17.74 Million USD | -16484.134% |
| Immunovant, Inc. | 666.71 Million USD | -341.324% |
| Quantum-Si incorporated | 298.25 Million USD | -886.54% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -1937.629% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -5332.712% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -1576.117% |
| Acasti Pharma Inc. | 73.3 Million USD | -3914.13% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -64534.784% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -11166.122% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -204.971% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -56593.709% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -12815.838% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -5601.911% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -1528.392% |
| PepGen Inc. | 143.05 Million USD | -1956.844% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -7599.079% |
| United Therapeutics Corporation | 7.16 Billion USD | 58.946% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -15236.758% |
| Solid Biosciences Inc. | 164.93 Million USD | -1683.906% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -50006.032% |
| Immuneering Corporation | 102.58 Million USD | -2768.227% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -68190.009% |
| Silo Pharma, Inc. | 7.74 Million USD | -37884.811% |
| Belite Bio, Inc | 94.64 Million USD | -3008.934% |
| XOMA Corporation | 234.3 Million USD | -1155.802% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -1161.796% |
| Bionomics Limited | 27.64 Million USD | -10541.785% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -633.016% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2639.931% |
| uniQure N.V. | 831.68 Million USD | -253.781% |
| Cassava Sciences, Inc. | 151.66 Million USD | -1840.063% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -65958.198% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -974.304% |
| Forte Biosciences, Inc. | 38.98 Million USD | -7448.376% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -72138.513% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -7888.806% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -40630.302% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -83656.248% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -24790.931% |
| Altimmune, Inc. | 210.64 Million USD | -1296.865% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -278.253% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2639.931% |
| Compugen Ltd. | 121.33 Million USD | -2325.006% |
| Peak Bio, Inc. | 2.59 Million USD | -113223.833% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -1607.427% |
| Benitec Biopharma Inc. | 52.21 Million USD | -5535.62% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -760.693% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -8361.614% |
| Zura Bio Limited | 100.84 Million USD | -2817.76% |
| PolyPid Ltd. | 15.37 Million USD | -19041.016% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -2366.641% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -8361.614% |
| Instil Bio, Inc. | 325.63 Million USD | -803.589% |
| argenx SE | 4.54 Billion USD | 35.225% |
| Immunome, Inc. | 148.54 Million USD | -1880.852% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -1775.606% |
| Verona Pharma plc | 308.12 Million USD | -854.926% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -3283.614% |
| Shattuck Labs, Inc. | 159.56 Million USD | -1743.998% |
| CervoMed Inc. | 9.97 Million USD | -29404.646% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -1461.297% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -25737.346% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -1540.064% |
| Moolec Science SA | 24.05 Million USD | -12133.677% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -47997.534% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -1601.331% |
| AnaptysBio, Inc. | 452.38 Million USD | -550.404% |
| Design Therapeutics, Inc. | 289.64 Million USD | -915.856% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -3940.312% |
| NeurAxis, Inc. | 509.49 Thousand USD | -577401.187% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -54207.069% |
| Lumos Pharma, Inc. | 40.63 Million USD | -7140.408% |
| Achilles Therapeutics plc | 161.45 Million USD | -1722.389% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -3283.614% |
| 180 Life Sciences Corp. | 5.25 Million USD | -55843.919% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -4077.835% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -34270.88% |
| Nutriband Inc. | 7.51 Million USD | -39041.901% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -1055.288% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -1376.338% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -3760.753% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -4980.387% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -458.81% |
| Palisade Bio, Inc. | 14.05 Million USD | -20839.062% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -1299.157% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -101.571% |
| Neurogene Inc. | 222.57 Million USD | -1221.974% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -355.036% |
| AEON Biopharma, Inc. | 6.84 Million USD | -42885.493% |
| Sesen Bio, Inc. | 189.17 Million USD | -1455.371% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -982.278% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -21358.466% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -277.056% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -1002.031% |
| Athira Pharma, Inc. | 160.24 Million USD | -1736.162% |
| Vaccinex, Inc. | 3.63 Million USD | -80934.343% |
| HCW Biologics Inc. | 28.51 Million USD | -10219.114% |
| XOMA Corporation | 234.3 Million USD | -1155.802% |
| Nektar Therapeutics | 398.03 Million USD | -639.224% |
| Arvinas, Inc. | 1.3 Billion USD | -125.537% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -17170.056% |
| Merus N.V. | 458.49 Million USD | -541.744% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -1339.749% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -1532.792% |
| Rezolute, Inc. | 132.73 Million USD | -2116.682% |
| Clene Inc. | 52.34 Million USD | -5521.515% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -19615.767% |
| BeyondSpring Inc. | 24.8 Million USD | -11760.517% |
| Synlogic, Inc. | 75.55 Million USD | -3794.582% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -24704.898% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -31322.01% |
| Peak Bio, Inc. | 2.59 Million USD | -113223.833% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -1582.953% |
| Krystal Biotech, Inc. | 818.35 Million USD | -259.545% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -1123.749% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -305.402% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -82153.673% |
| MannKind Corporation | 475.19 Million USD | -519.185% |
| Ikena Oncology, Inc. | 192.09 Million USD | -1431.744% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -21900.576% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -2424.783% |
| Gossamer Bio, Inc. | 311.91 Million USD | -843.317% |
| CohBar, Inc. | 16.36 Million USD | -17878.839% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -8267.764% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -40123.609% |
| Legend Biotech Corporation | 1.84 Billion USD | -59.166% |
| Mural Oncology plc | 301.74 Million USD | -875.114% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -9326.1% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -51698.366% |
| Disc Medicine, Inc. | 367.99 Million USD | -699.562% |
| Champions Oncology, Inc. | 26.13 Million USD | -11159.594% |
| REGENXBIO Inc. | 573.97 Million USD | -412.633% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -108550.836% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1805.844% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -24266.175% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -765.31% |
| Vaxart, Inc. | 91.83 Million USD | -3104.135% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -4811.797% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -1883.697% |
| Cellectis S.A. | 334.27 Million USD | -780.234% |
| Longeveron Inc. | 12.17 Million USD | -24061.25% |
| Repare Therapeutics Inc. | 253.9 Million USD | -1058.86% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 9.87% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -1364.974% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -40.878% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -180968.123% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -959.503% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -1704.042% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -2020.709% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -11428.709% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 87.055% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -154.989% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -23992.78% |
| Veru Inc. | 50.59 Million USD | -5715.403% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -6359.195% |
| Cingulate Inc. | 3.49 Million USD | -84173.548% |
| Passage Bio, Inc. | 150.54 Million USD | -1854.47% |
| Context Therapeutics Inc. | 16.06 Million USD | -18217.908% |
| Exicure, Inc. | 11.58 Million USD | -25308.955% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -682.442% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -1720.292% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -16740.413% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -784.268% |
| Nuvalent, Inc. | 732.38 Million USD | -301.751% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -19589.116% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -3185.567% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -20633.965% |
| OmniAb, Inc. | 401.98 Million USD | -631.957% |
| Anew Medical, Inc. | 19.45 Million USD | -15023.171% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -10909.114% |
| Lipocine Inc. | 23 Million USD | -12692.26% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -2004.585% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -862.923% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3405.257% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -2320.896% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -36980.744% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -233.496% |
| Ocugen, Inc. | 64.54 Million USD | -4458.472% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -2262.561% |
| Q32 Bio Inc. | 306.11 Million USD | -861.181% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -69822.933% |
| Alumis Inc. Common Stock | 89.61 Million USD | -3183.441% |
| Equillium, Inc. | 50.53 Million USD | -5722.99% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -3812.969% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -7028.921% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -172893.022% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -11155.717% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -4465.97% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -78844.668% |
| Dominari Holdings Inc. | 57.55 Million USD | -5011.986% |
| Edesa Biotech, Inc. | 8.89 Million USD | -32995.752% |
| vTv Therapeutics Inc. | 11.01 Million USD | -26605.001% |
| Bio-Techne Corporation | 2.81 Billion USD | -4.591% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -213.979% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -262.606% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -959.679% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -6955.674% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -340.744% |
| Nkarta, Inc. | 378.88 Million USD | -676.583% |
| BioCardia, Inc. | 2.98 Million USD | -98405.424% |
| Iterum Therapeutics plc | 26.25 Million USD | -11105.137% |